Certara, Inc. $CERT Holdings Raised by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP grew its stake in shares of Certara, Inc. (NASDAQ:CERT – Free Report) by 341.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 63,508 shares of the company’s stock after buying an additional 49,138 shares during the period. Fulcrum Asset Management LLP’s holdings in Certara were worth $588,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in CERT. Childress Capital Advisors LLC increased its position in Certara by 85.8% during the 3rd quarter. Childress Capital Advisors LLC now owns 24,221 shares of the company’s stock worth $223,000 after purchasing an additional 11,186 shares in the last quarter. North Star Investment Management Corp. acquired a new position in Certara in the 3rd quarter valued at about $800,000. GAMMA Investing LLC lifted its holdings in Certara by 21.2% in the 3rd quarter. GAMMA Investing LLC now owns 9,778 shares of the company’s stock valued at $90,000 after purchasing an additional 1,710 shares in the last quarter. Sequoia Financial Advisors LLC lifted its holdings in Certara by 12.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 17,906 shares of the company’s stock valued at $117,000 after purchasing an additional 1,923 shares in the last quarter. Finally, NorthRock Partners LLC acquired a new stake in shares of Certara during the 2nd quarter worth about $68,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Price Performance

Shares of Certara stock opened at $11.57 on Monday. The business’s fifty day moving average price is $9.70 and its 200 day moving average price is $7.40. Certara, Inc. has a twelve month low of $4.45 and a twelve month high of $12.61. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $1.76 billion, a P/E ratio of -27.55 and a beta of 1.30.

Certara (NASDAQ:CERT – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.09 EPS for the quarter, hitting the consensus estimate of $0.09. The company had revenue of $94.90 million during the quarter, compared to analyst estimates of $92.01 million. Certara had a positive return on equity of 3.36% and a negative net margin of 16.14%. The firm’s revenue was down 9.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. As a group, research analysts anticipate that Certara, Inc. will post 0.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CERT. Jefferies Financial Group reiterated a “hold” rating and set a $12.00 price target on shares of Certara in a report on Friday, November 6th. Weiss Ratings upgraded shares of Certara from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, November 9th. TD Cowen lifted their target price on shares of Certara from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. KeyCorp lifted their target price on shares of Certara from $9.00 to $12.00 and gave the stock an “overweight” rating in a research note on Friday, October 16th. Finally, Barclays increased their price target on Certara from $9.00 to $12.00 and gave the stock an “equal weight” rating in a research note on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $9.92.

Get Our Latest Research Report on Certara

About Certara

(Free Report)

Certara provides software and consulting services that support the development and use of medicines. Its biosimulation tools help pharmaceutical and biotechnology companies model how drugs behave in the body, assess potential treatment outcomes, and inform decisions during drug research and development. The company’s offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial simulation, and drug development analysis. Certara also provides scientific and regulatory consulting, including support for regulatory submissions and strategies that use modeling and simulation to guide development programs.

Further Reading

Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERT – Free Report).

Institutional Ownership by Quarter for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.